The Effects of Alendronate After Cure of Primary Hyperparathyroidism (AlenPostPara)
Hyperparathyroidism
About this trial
This is an interventional treatment trial for Hyperparathyroidism focused on measuring primary hyperparathyroidism, hyperparathyroidism, PHPT, PTH, hypercalcemia, bone density, osteoporosis, bone turnover, DXA, pQCT, cQCT, alendronate, Fosamax, parathyroid hormone, parathyroid surgery, parathyroidectomy, Silverberg, Rubin, Bilezikian, treatment
Eligibility Criteria
Inclusion Criteria: patients with PHPT who have a negative T-score by BMD at the lumbar spine before surgery; successful surgery for PHPT as documented by normalization of serum calcium and PTH levels within 1 week of study initiation. Exclusion Criteria: vitamin D deficiency; any concomitant disease that might affect mineral metabolism such as hyperthyroidism, Paget's disease of bone, diabetes mellitus, chronic liver or renal disease, acromegaly, Cushing's syndrome, rheumatoid arthritis, myeloma; any woman who is within 5 years of the menopause; gastrointestinal disorders, surgery or drugs affecting absorption; treatment with a bisphosphonate within 2 years of parathyroidectomy; treatment with any of the following medications more recently than 6 months prior to enrollment: estrogens, progestins, raloxifene, calcitonin, systemic corticosteroids, fluoride, lithium, loop diuretics, methotrexate; abnormalities of the esophagus which delay esophageal emptying such as stricture or achalasia; inability to stand or sit upright for at least 30 minutes; increased risk of aspiration; hypersensitivity to alendronate; hypocalcemia; pregnancy or nursing; (women within childbearing years will be advised not to conceive during the study); age < 18 years old.
Sites / Locations
- CUMC
Arms of the Study
Arm 1
Arm 2
Active Comparator
Placebo Comparator
Alendronate 70mg weekly
placebo of alendronate 70mg weekly
Alendronate 70mg weekly
placebo of Alendronate 70mg weekly